非小细胞肺癌新辅助免疫治疗:当前概念与未来方向
本文综述可切除非小细胞肺癌(NSCLC)新辅助免疫治疗的证据。既往32项随机试验的系统评价显示术前与术后化疗生存无差异,但近期在研试验的早期数据提示新辅助免疫治疗可能显著有效并改善生存。文章讨论治疗「成功」定义、监管获批障碍及未来方向。
要点
- 可切除NSCLC术后复发风险高,数十年治疗进展有限。
- 32项随机试验系统评价显示术前与术后化疗生存无差异。
- 新辅助免疫治疗早期数据提示可能显著有效并改善生存。
核心结论
- 新辅助免疫治疗在可切除NSCLC多模式治疗中显示潜力,但需统一治疗「成功」定义并克服监管障碍。
研究设计与样本
- 综述文章,汇总正在进行的临床试验早期结果,并讨论可切除NSCLC新辅助免疫治疗的证据。
主要发现
- 32项随机试验涉及10000例患者的系统评价显示术前与术后化疗生存无差异。
- 近期在研试验早期数据提示新辅助免疫治疗可能显著有效并改善可切除NSCLC患者生存。
关键数值与推荐
- 32项随机试验涉及10000例患者,术前与术后化疗生存无差异。
临床怎么用
- 新辅助免疫治疗可作为可切除NSCLC多模式管理的潜在选择,但尚未确立为标准治疗。
局限性
- 治疗「成功」缺乏统一定义,监管获批存在障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer is the leading cause of cancer-related deaths worldwide. Patients with resectable NSCLC are often treated with surgery and adjuvant chemotherapy. However, these patients continue to have a high risk of recurrence and death. Unfortunately, there has been little progress in the treatment of resectable NSCLC over the past several decades. Neoadjuvant therapy, which has been considered as an approach to improve survival in patients with resectable NSCLC, is a hotly debated topic. A systematic review of 32 randomized trials involving 10,000 patients revealed that there was no difference in survival between preoperative and postoperative chemotherapy. Because of such results and the theoretical concern about resectable tumors progressing on relatively ineffective neoadjuvant chemotherapy, and thus becoming unresectable, neoadjuvant chemotherapy fell out of favor, and many clinicians preferred adjuvant chemotherapy after surgery. However, neoadjuvant therapy has been revived in the past couple of years, with emerging data from various ongoing trials suggesting that neoadjuvant immunotherapy may have significant efficacy and could potentially improve the survival of patients with resectable NSCLC. In this review article, we discuss the evidence supporting the role of neoadjuvant immunotherapy in the multimodal management of resectable NSCLC. We summarize early results of ongoing clinical trials and highlight the challenges in adopting a uniform definition of treatment "success." We address hurdles to be overcome for seeking regulatory approval for neoadjuvant immunotherapy and establishing it as a standard of care. Finally, we provide some perspectives for the future.
引用
- Uprety D, Mandrekar SJ, Wigle D, et al. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches. J Thorac Oncol. 2020. PMID: 32522713. doi:10.1016/j.jtho.2020.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。